The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Microbial Contract Manufacturing

Microbial Contract Biomanufacturing Market, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    September 2020

  • Pages
    240

  • View Count
    1221

  • Order Now

Example Insights

Microbial-Contract-Biomanufacturing-Market-Context Microbial-Contract-Biomanufacturing-Market-List-of-microbial Microbial-Contract-Biomanufacturing-Market-Distribution-by-Scale-of-Operation
Microbial-Contract-Biomanufacturing-Market-Distribution-by-Location Microbial-Contract-Biomanufacturing-Market-Company-Competitiveness-Analysis Microbial-Contract-Biomanufacturing-Market-Recent-Developments
Microbial-Contract-Biomanufacturing-Market-Big-Pharma-Initiatives Microbial-Contract-Biomanufacturing-Market-Future-Forecast Microbial-Contract-Biomanufacturing-Market-Segments

 

Overview

Traditionally, microbial cell cultures have been the preferred choice for the production of the variety of biologics, including peptide therapeutics and certain low molecular weight proteins (insulin) and cytokines. Till date, over 60% of recombinant proteins used for therapeutic purposes, are estimated to be produced using microbial expression systems, primarily Escherichia coli. In fact, more than 70 biologics approved by various regulatory authorities, worldwide, are manufactured using microbial fermentation. It is worth highlighting that the growing interest in certain novel biologics, such as antibody fragments and plasmid DNA (with potential application areas in cell and gene therapies, and DNA vaccines), has led to a substantial increase in demand for microbial system-based production. Furthermore, evolutionary advances in manufacturing technologies have resulted in a renewed interest from drug developers in using microbial platforms for the production of complex biologics. 

Given the inherent complexities in the development and production of biologics, drug developers have demonstrated the preference to outsource parts of their microbial manufacturing operations, as well. In fact, there has been a rise in the outsourcing activity in relation to microbial fermentation since 2017. Presently, the microbial contract biomanufacturing market features a mix of small, mid-sized and large players, offering end-to-end solutions, ranging from early stage process development to clinical and commercial scale manufacturing and regulatory filing. Despite this being a fairly well-established domain, more than 25 new contract microbial fermentation companies have been established over the last decade. Therefore, in order to remain competitive, CMOs / CDMOs have begun active in acquiring cutting-edge fermentation technologies and investing in the development of the necessary capacity to support the growing demand for novel biologics. It is also worth highlighting that the COVID-19 pandemic is also likely to create significant business opportunities for microbial CMOs as innovator companies are expected to seek support in manufacturing of potential vaccines and other therapeutic modalities. In the long term, we are led to believe that the contract services market catering to this segment of the biopharma industry is anticipated to witness substantial growth in the coming years.

Scope of the Report

The “Microbial Contract Biomanufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • A detailed review of the current landscape of companies offering contract manufacturing services for biologics, using microbial expression systems, along with information on their year of establishment, company size, location of headquarters, number and location of their production facilities, scale of operation (preclinical, clinical and commercial), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, biosimilars, oligonucleotides, plasmid DNA and others), type of microbial expression system(s) used (bacterial, yeast and others), type of fermenter(s) employed (single-use fermenters, stainless steel fermenters and others), type of manufacturing service(s) offered (cell banking, process development and characterization, analytical method development and testing, quality assurance and control, scale-up, downstream processing and regulatory support), and regulatory accreditations / certifications received (if any). 
  • A region-wise, company competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing based on their experience (considering the year of establishment of the firm) and expertise (taking into account their service portfolio, number of different types of biologics manufactured and number of distinct expression system(s) used).
  • An analysis of the various partnerships signed within this domain, with a focus on microbial contract biomanufacturing, since 2016, based on several relevant parameters, such as year of partnership, type of partnership model adopted, scale of operation, type of biologic, focus area, therapeutic area, most active players (in terms of number of partnerships signed), and geography. Further, it features a detailed analysis of the various mergers and acquisitions that were carried out in this domain, highlighting the trend in terms of number of players acquired between 2016-2020 (till May), along with the geographical distribution of this activity. 
  • An elaborate analysis of the various expansion initiatives undertaken by contract manufacturers using microbial expression systems in order to augment their capabilities, over the period 2016-2020 (till May), taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation of manufacturing facility, type of biologic and location of manufacturing facility.
  • A review of the varied microbial based manufacturing initiatives undertaken by big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), highlighting trends across various parameters, such as number of initiatives, year of initiative and type of initiative.
  • A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
  • Elaborate profiles of key players that offer contract biomanufacturing services using microbial expression systems across different geographies, namely North America, Europe and Asia Pacific. Each profile features a brief overview of the company, information related to its service portfolio, manufacturing capabilities and facilities, recent developments and an informed future outlook.  
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
  • An insightful discussion on the impact of COVID-19 outbreak on the overall microbial contract biomanufacturing market, and the key initiatives undertaken by CMOs to combat the challenges posed due to ongoing situation.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the microbial contract biomanufacturing market. Based on multiple parameters, such as projected growth of the overall microbial biomanufacturing market, cost of goods sold and direct manufacturing costs, we developed informed estimates describing the financial evolution of the market, over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of biologic (proteins, vaccines and others) [B] type of microbial expression system used (bacterial, yeast and others) [C] scale of operation (preclinical / clinical and commercial) [D] end user (small, mid-sized and large / very large), and [E] key geographical regions (North America, Europe and Asia Pacific, Middle East and North Africa and Latin America). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals)
  • Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
  • Andrea Conforto (Sales and Marketing, Bioservices Director, Olon)
  • Max Rossetto (General Manager, Business Development, Luina Bio)
  • Rob van Dijk (Business Development Manager, WACKER Biotech)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading CMOs with expertise in production of microbial biologics?
  • What are the preferred microbial expression systems used in biologic development and manufacturing?
  • What are the key microbial fermentation technology platforms?
  • Who could be the potential partners for the microbial CMOs?
  • What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
  • What type of expansion initiatives are being carried out by CMOs in this domain?
  • What initiatives are being undertaken by big pharma players in this domain? 
  • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to microbial fermentation?
  • What are the key trends within the microbial contract biomanufacturing market?
  • How is the current and future market opportunity likely to be distributed across key market segments? 

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the microbial contract biomanufacturing market and its likely evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction to biopharmaceuticals and biopharmaceutical manufacturing processes. The chapter also includes an overview of the various microbial expression systems used for the development of different types of biologics. Further, it features a brief overview of contract manufacturing and includes a detailed discussion on the need for outsourcing within the microbial biopharmaceutical industry. In this chapter, we have presented a list of commonly outsourced microbial biomanufacturing activities; the chapter concludes with a discussion on the challenges that are currently faced by players engaged in the market.

Chapter 4 provides an overview of the current microbial contract biomanufacturing landscape. It includes information on close to 115 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, scale of operation, geographical location of the headquarters, number and location of production facilities, type of biologics manufactured, type of microbial expression system used, type of fermenter used, type of services offered, and regulatory accreditations / certifications received (if any). 

Chapter 5 provides a detailed 3-D company competitiveness analysis of microbial contract manufacturers based in North America, Europe, Asia Pacific and Middle East, that we came across during our research. The analysis compares companies within each geography on the basis of company experience (considering the experience of contract manufacturer) and company expertise (which takes into account the count of service portfolio, number of biologics manufactured, number of expression system used and scale of operation).

Chapter 6 features detailed profiles of key industry players that offer contract biomanufacturing services using microbial expression systems across different geographies such as, North America, Europe and Asia Pacific and Middle East, at all scales of operation. Each profile features a brief overview of the company, information related to its service portfolio, manufacturing capabilities and facilities, and an informed future outlook.

Chapter 7 features an elaborate analysis of the various partnerships that have been inked amongst players in this domain, in the time period 2016-2020. It provides a brief description on the various types of partnership model (which include manufacturing agreements, product development agreements, process development agreement, service alliances, and others) that have been adopted by stakeholders in this domain. Further, it features the detailed analysis based on the year of agreement, partnership model, scale of operation, type of biologic, focus area of the deal, therapeutic area and most active players. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents. In addition, it features a detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2016-2020, along with the geographical distribution of this activity. 

Chapter 8 presents detailed analysis on the various expansion initiatives undertaken by contract biomanufacturers using microbial expression systems, in order to augment their capabilities, over the period 2016-2020. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain. 

Chapter 9 provides a list of microbial fermentation technology platforms that are either available in the market. In addition, it features a list of emerging microbial fermentation technologies. 

Chapter 10 features a proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments. 

Chapter 11 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by biopharmaceutical therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of CMOs.

Chapter 12 provides a detailed analysis of microbial based biopharmaceuticals manufacturing related initiatives of the big pharma players (shortlisted from the top companies of 2019 by revenues), featuring trends across various parameters, such as number of initiatives, year of initiative and type of initiatives.

Chapter 13 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes. 

Chapter 14 presents a detailed market forecast analysis, highlighting the likely growth of the microbial contract biomanufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] distribution by type of biologics (proteins, vaccines and others) [B] type of microbial expression system used (bacterial, yeast and others) [C] type by scale of operation (preclinical / clinical and commercial) [D] end user (small, mid-sized and large / very large), and [E] key geographical regions (North America, Europe and Asia Pacific, Middle East and North Africa and Latin America).

Chapter 15 highlights the effect of coronavirus outbreak on the global microbial contract biomanufacturing industry. It includes a brief discussion on the short-term and long-term impact of COVID-19 upsurge on the supply chain and market opportunity for drug developers and CMOs to combat the challenges posed due to ongoing situation. In addition, it includes a brief section on strategies and action plans that biopharma companies are likely to adopt in order to prepare for supply chain disruptions in future.

Chapter 16 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of microbial contract biomanufacturing market, under a SWOT framework.

Chapter 17 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the microbial contract biomanufacturing market, based on the research and analysis described in the previous chapters. 

Chapter 18 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals), Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories),     Andrea Conforto (Sales and Marketing, Bioservices Director, Olon), Max Rossetto (General Manager, Business Development, Luina Bio) and Rob van Dijk (Business Development Manager, WACKER Biotech).

Chapter 19 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 20 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1 Chapter Overview
3.2. Overview of Biopharmaceuticals

3.3. Expression Systems Used for Biopharmaceutical Production
3.3.1. Microbial Expression Systems
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Fungal Expression Systems
3.3.1.3. Yeast Expression Systems
3.3.2. Mammalian versus Microbial Expression Systems

3.4. Microbial Manufacturing Process
3.4.1. Cell Banking
3.4.2. Upstream Processing
3.4.3. Fermentation
3.4.4. Downstream Processing

3.5. Overview of Contract Manufacturing
3.6. Need for Outsourcing Microbial Biomanufacturing Operations
3.7. Commonly Outsourced Microbial Biomanufacturing Operations 
3.8. Advantages and Risks Associated with Outsourcing Microbial Biomanufacturing                
3.9. Key Considerations while Selecting a CMO Partner
3.10. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Microbial Contract Biomanufacturing Market: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Manufacturing Facility
4.2.5. Analysis by Scale of Operation 
4.2.6. Analysis by Type of Biologic
4.2.7. Analysis by Type of Expression System Used
4.2.8. Analysis by Type of Fermenter 
4.2.9. Analysis by Type of Service(s) Offered
4.2.10. Analysis by Regulatory Accreditations / Certifications 
4.3. Regional Analysis
4.3.1. Analysis by North America
4.3.2. Analysis by Europe
4.3.3. Analysis by Asia Pacific
4.3.4. Analysis by Middle East and North Africa

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Competitiveness Analysis
5.4.1. Competitiveness Analysis: Companies in North America
5.4.2. Competitiveness Analysis: Companies in Europe
5.4.3. Competitiveness Analysis: Companies in Asia Pacific

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Microbial Contract Biomanufacturers based in North America
6.2.1. AGC Biologics
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Manufacturing Capabilities and Facilities
6.2.1.4. Recent Developments and Future Outlook

6.2.2. Aldevron
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Manufacturing Capabilities and Facilities
6.2.2.4. Recent Developments and Future Outlook
6.2.3. BioVectra
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Manufacturing Capabilities and Facilities
6.2.3.4. Recent Developments and Future Outlook

6.2.4. Ology Bioservices
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Manufacturing Capabilities and Facilities
6.2.4.4. Recent Developments and Future Outlook

6.3. Microbial Contract Biomanufacturers Based in Europe
6.3.1. Eurogentec
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Manufacturing Capabilities and Facilities
6.3.1.4. Recent Developments and Future Outlook

6.3.2. Northway Biotechpharma
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Manufacturing Capabilities and Facilities
6.3.2.4. Recent Developments and Future Outlook

6.3.3. Porton Biopharma
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Manufacturing Capabilities and Facilities
6.3.3.4. Recent Developments and Future Outlook

6.4. Microbial Contract Biomanufacturers Based in Asia Pacific
6.4.1. EirGenix
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Manufacturing Capabilities and Facilities
6.4.1.4. Recent Developments and Future Outlook

6.4.2. Etinpro
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Manufacturing Capabilities and Facilities
6.4.2.4. Recent Developments and Future Outlook

6.4.3. Stelis Biopharma
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Capabilities and Facilities
6.4.3.4. Recent Developments and Future Outlook

7. RECENT PARTNERSHIPS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Microbial Contract Biomanufacturers: Recent Partnerships
7.3.1. Analysis by Year of Partnerships
7.3.2. Analysis by Type of Partnership Model
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Type of Biologic
7.3.5. Analysis by Focus Area
7.3.6. Analysis by Target Therapeutic Area

7.3.7. Analysis by Region
7.3.7.1. Country-Wise Distribution
7.3.7.2. Intercontinental and Intracontinental Agreements

7.3.8. Most Active Players: Analysis by Number of Partnerships

7.4. Microbial Contract Biomanufacturers: Mergers and Acquisitions
7.4.1. Analysis by Year of Merger / Acquisition
7.4.2. Analysis by Type of Acquisition  
7.4.3. Regional Analysis  
7.4.3.1. Continent-wise Distribution
7.4.3.2. Country-wise Distribution
7.4.3.3. Intercontinental and Intracontinental Deals

7.4.4. Most Active Players: Analysis by Number of Acquisitions 
7.4.5. Analysis by Key Value Drivers   
7.4.5.1. Analysis by Year of Acquisition and Key Value Drivers

8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Microbial Contract Biomanufacturers: Recent Expansions 
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Scale of Operation
8.2.4. Analysis by Type of Biologic
8.3. Geographical Analysis
8.3.1. Continent-wise Distribution

9. MICROBIAL FERMENTATION TECHNOLOGY PLATFORMS
9.1. Chapter Overview
9.2. Technology Platforms Commonly Used for Microbial Fermentation
9.3. Upcoming Platforms-General Technologies 

10. ASSESSMENT OF RELATIVE COMPETITION AND GROWTH 
10.1. Chapter Overview
10.2. Assumptions and Methodology
10.3. Analysis of Relative Competition and Growth Opportunities 
10.3.1. Established Biologics in Emerging Region
10.3.2. Established Biologics in Established Region
10.3.3. Emerging Biologics in Emerging Region
10.3.4. Emerging Biologics in Established Region

11. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
11.1. Chapter Overview
11.2. Assumptions and Parameter Definitions
11.2.1. Scenario 1
11.2.2. Scenario 2
11.2.3. Scenario 3
11.2.4. Scenario 4
11.3. Concluding Remarks 

12. BIG PHARMA INITITATIVES IN MICROBIAL BIOMANUFACTURING
12.1. Chapter Overview
12.2. List of Microbial Biomanufacturing Initiatives of Big Pharma Players
12.2.1. Analysis by Number of Initiatives
12.2.2. Analysis by Year of Initiative
12.2.3. Analysis by Purpose of Initiative
12.2.4. Analysis by Type of Initiative
12.2.5. Analysis by Development Scale
12.2.6. Analysis by Type of Drug Molecule
12.2.7. Analysis by Type of Microbial Expression System Used
12.2.8. Analysis by Year of Initiative and Company 
12.2.9. Analysis by Purpose of Initiative and Company
12.2.10. Geographical Analysis by Investment Made

12.3. Competitive Benchmarking of Big Pharma Players
12.3.1. Big Pharma Summary

13. CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE 
13.1. Chapter Overview
13.2. Small Molecule and Large Molecule Drugs / Therapies
13.2.1. Comparison of Key Characteristics
13.2.2. Comparison of Microbial Manufacturing Processes
13.2.2.1. Microbial Contract Manufacturers Providing Services for Small Molecules
13.2.3. Comparison of Key Microbial Manufacturing Challenges

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Forecast Methodology
14.3. Overall Microbial Contract Biomanufacturing Market, 2020-2030
14.3.1. Microbial Contract Biomanufacturing Market for APIs, 2020-2030
14.3.2. Microbial Contract Biomanufacturing Market for FDFs, 2020-2030

14.4. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Biologic
14.5. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Microbial Expression System Used
14.6. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Scale of Operation
14.7. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by End User

14.8. Microbial Contract Biomanufacturing Market, 2020, 2025, 2030: Distribution by Key Geographical Regions
14.8.1. Microbial Contract Biomanufacturing Market in North America, 2020-2030
14.8.1.1. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Proteins
14.8.1.3. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Enzymes
14.8.1.4. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Growth Hormones
14.8.1.5. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Antibody based Drugs
14.8.1.6. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Biologics
14.8.1.7. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.1.8. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.1.9. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.1.10. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Commercial Operations
14.8.1.11. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations
14.8.1.12. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Small Companies
14.8.1.13. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
14.8.1.14. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies

14.8.2. Microbial Contract Biomanufacturing Market in Europe, 2020-2030
14.8.2.1. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Proteins
14.8.2.2. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Enzymes
14.8.2.3. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Growth Hormones
14.8.2.4. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Antibody based Drugs
14.8.2.5. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Biologics
14.8.2.6. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.2.7. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.2.8. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.2.9. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Commercial Operations
14.8.2.10. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations
14.8.2.11. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Small Companies
14.8.2.12. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
14.8.2.13. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies

14.8.3. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030
14.8.3.1. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Proteins
14.8.3.2. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Enzymes
14.8.3.3. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Growth Hormones
14.8.3.4. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Antibody based Drugs
14.8.3.5. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Biologics
14.8.3.6. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.3.8. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.3.9. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations
14.8.3.10. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations
14.8.3.11. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies
14.8.3.12. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies
14.8.3.13. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies

14.8.3. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030
14.8.3.1. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins
14.8.3.2. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Enzymes
14.8.3.3. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Growth Hormones
14.8.3.4. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Antibody based Drugs
14.8.3.5. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Biologics
14.8.3.6. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.3.6. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations
14.8.3.8. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations
14.8.3.9. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Small Companies
14.8.3.10. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Mid-sized Companies
14.8.3.11. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Large / Very Large Companies

14.8.3. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030
14.8.3.1. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Proteins
14.8.3.2. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Enzyme
14.8.3.3. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Growth Hormone
14.8.3.4. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Antibody based Drug
14.8.3.5. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Biologics
14.8.3.6. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.3.8. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.3.9. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Commercial Operations
14.8.3.10. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Preclinical / Clinical Operations
14.8.3.11. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Small Companies
14.8.3.12. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Mid-sized Companies
14.8.3.13. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Large / Very Large Companies

15. IMPACT OF COVID-19 PANDEMIC ON MICROBIAL CONTRACT BIOMANUFACTURING MARKET
15.1. Chapter Overview
15.2. Current Options and Recuperative Initiatives of Key Players
15.2.1. KBI Biopharma
15.2.2. Lonza
15.2.3. Porton Pharma Solutions
15.2.4. Wacker Biotech
15.2.5. Wuxi AppTec
15.3. Impact on Microbial Contract Biomanufacturing Market Opportunity

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors

17. CONCLUSION
17.1. Chapter Overview
17.2. Key Takeaways

18. INTERVIEW TRANSCRIPTS
18.1. Chapter Overview
18.2. Meteoric Biopharmaceuticals
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Gaurav Kaushik (Chief Executive Officer and Managing Director)

18.3. List Biological Laboratories
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Debbie Pinkston (Vice President, Sales and Business Development)

18.4. Olon
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Andrea Conforto (Sales and Marketing, Bioservices Director)
18.5. Luina Bio
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Max Rossetto (General Manager, Business Development)

18.6. WACKER Biotech
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Rob van Dijk (Business Development Manager)

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

List Of Figures

Figure 3.1. Biopharmaceuticals Expressed in Microbial Expression Systems
Figure 3.2. Types of Expression System
Figure 3.3. Sequential Stages of the Microbial Manufacturing Process
Figure 3.4. Master and Working Cell Bank Systems
Figure 3.5. Types of Third-Party Service Providers
Figure 3.6. Commonly Outsourced Microbial Contract Biomanufacturing Operations
Figure 3.7. Advantages and Disadvantages Associated with Outsourcing Manufacturing
Figure 4.1. Microbial Contract Biomanufacturers: Distribution by Year of Establishment
Figure 4.2 Microbial Contract Biomanufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 4.3. Microbial Contract Biomanufacturers: Distribution by Company Size
Figure 4.4. Microbial Contract Biomanufacturers: Distribution by Location of
Figure 4.5. Microbial Contract Biomanufacturers: Distribution by Location of Manufacturing Facilities (Country-Wise)
Figure 4.6. Microbial Contract Biomanufacturers: Distribution by Scale of Operation
Figure 4.7. Microbial Contract Biomanufacturers: Distribution by Type of Biologics Manufactured
Figure 4.8. Microbial Contract Biomanufacturers: Distribution by Type of Expression System Used
Figure 4.9. Microbial Contract Biomanufacturers: Distribution by Type of Fermenter Used
Figure 4.10. Microbial Contract Biomanufacturers: Distribution by Type of Service(s) Offered
Figure 4.11. Microbial Contract Biomanufacturers: Distribution by Regulatory Accreditations / Certifications Obtained
Figure 4.12. Regional Capability Analysis: North America
Figure 4.13. Regional Capability Analysis: Europe
Figure 4.14. Regional Capability Analysis: Asia Pacific and Middle East
Figure 5.1. Company Competitiveness Analysis: Microbial Contract Biomanufacturing in North America
Figure 5.2. Company Competitiveness Analysis: Microbial Contract Biomanufacturing in Europe
Figure 5.3. Company Competitiveness Analysis: Microbial Contract Biomanufacturing in Asia Pacific
Figure 6.1. AGC Biologics: Service Portfolio
Figure 6.2. Aldevron: Service Portfolio
Figure 6.3. BioVectra: Service Portfolio
Figure 6.4. Ology Bioservices: Service Portfolio
Figure 6.5. Eurogentec: Service Portfolio
Figure 6.6. Northway Biotechpharma: Service Portfolio
Figure 6.7. Porton Biopharma: Service Portfolio
Figure 6.8. EirGenix: Service Portfolio
Figure 6.9. Etinpro: Service Portfolio
Figure 6.10. Stelis Biopharma: Service Portfolio
Figure 7.1. Recent Partnerships: Cumulative Distribution by Year of Partnership
Figure 7.2. Recent Partnerships: Distribution by Type of Partnership
Figure 7.3. Recent Partnerships: Year-wise Trend by Type of Partnership
Figure 7.4. Recent Partnerships: Distribution by Scale of Operation
Figure 7.5. Recent Partnerships: Distribution by Type of Biologic
Figure 7.6. Recent Partnerships: Distribution by Focus Area
Figure 7.7. Recent Partnerships: Distribution by Target Therapeutic Area
Figure 7.8. Recent Partnerships: Country-Wise Distribution
Figure 7.9. Recent Partnerships: Intercontinental and Intracontinental Deals
Figure 7.10. Recent Partnerships: Most Active Players
Figure 7.11. Acquisitions: Distribution by Year of Acquisition
Figure 7.12. Acquisitions: Distribution by Type of Acquisition
Figure 7.13. Acquisitions: Country-wise Distribution
Figure 7.14. Acquisitions: Intercontinental and Intracontinental Acquisitions
Figure 7.15. Acquisitions: Key Value Drivers
Figure 8.1. Recent Expansions: Cumulative Distribution by Year of Expansion, 2016-2020
Figure 8.2. Recent Expansions: Distribution by Type of Expansion
Figure 8.3. Recent Expansions: Distribution by Scale of Operation
Figure 8.4. Recent Expansions: Distribution by Type of Biologic
Figure 8.5. Recent Expansion: Distribution by Geography
Figure 10.1. Relative Competition and Growth Opportunities: Analytical Output
Figure 10.2. Relative Competition and Growth Opportunities Related to Established
Figure 10.3. Relative Competition and Growth Opportunities Related to Established
Figure 10.4. Relative Competition and Growth Opportunities Related to Emerging
Figure 10.5. Relative Competition and Growth Opportunities Related to Emerging
Figure 11.1. Make versus Buy Decision Making Framework
Figure 11.2. Make versus Buy Decision Making: Possible Scenarios
Figure 12.1. Big Pharma Players: Distribution by Number of Microbial Biomanufacturing Focused Initiatives
Figure 12.2. Big Pharma Players: Cumulative Distribution by Year of Initiative
Figure 12.3. Big Pharma Players: Distribution by Purpose of Initiative
Figure 12.4. Big Pharma Players: Distribution by Type of Initiative
Figure 12.5. Big Pharma Players: Distribution by Development Scale
Figure 12.6. Big Pharma Players: Distribution by Type of Drug Molecule
Figure 12.7. Big Pharma Players: Distribution by Type of Biologic Manufactured
Figure 12.8. Big Pharma Players: Distribution by Type of Microbial Expression System Used
Figure 12.9. Big Pharma Players: Distribution by Year of Initiative and Company
Figure 12.10. Big Pharma Players: Distribution by Purpose of Initiative and Company
Figure 12.11. Big Pharma Players: Distribution by Location of Initiative
Figure 12.12. Big Pharma Players: Distribution by Location of Initiative and Company
Figure 12.13. Harvey Ball Analysis: Big Pharma Summary
Figure 13.1. Small Molecules versus Large Molecules: Comparison of Key Characteristics
Figure 13.2. Small Molecules versus Large Molecule: Comparison of Manufacturing Process
Figure 13.3. Microbial Contract Biomanufacturing: Distribution by Type of Product
Figure 13.4. Microbial Contract Biomanufacturing: Distribution by Type of Expression System
Figure 14.1 Overall Microbial Contract Biomanufacturing Market, 2020-2030 (USD Billion)
Figure 14.2. Microbial Contract Biomanufacturing Market for APIs, 2020-2030 (USD Billion)
Figure 14.3. Microbial Contract Biomanufacturing Market for FDFs, 2020-2030 (USD Billion)
Figure 14.4. Microbial Contract Biomanufacturing Market: Distribution by Type of Biologic, 2020, 2025 and 2030
Figure 14.5. Microbial Contract Biomanufacturing Market: Distribution by Type of Microbial Expression System Used, 2020, 2025 and 2030
Figure 14.6. Microbial Contract Biomanufacturing Market: Distribution by Scale of Operation, 2020, 2025 and 2030
Figure 14.7. Microbial Contract Biomanufacturing Market: Distribution by Type of End User, 2020, 2025 and 2030
Figure 14.8. Microbial Contract Biomanufacturing Market: Distribution by Key Geographical Regions, 2020, 2025 and 2030
Figure 14.9. Microbial Contract Biomanufacturing Market in North America, 2020-2030 (USD Billion)
Figure 14.10. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Proteins (USD Billion)
Figure 14.11. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Enzymes (USD Billion)
Figure 14.12. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Growth Hormones (USD Billion)
Figure 14.13. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Antibody based drugs (USD Billion)
Figure 14.14. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Biologics (USD Billion)
Figure 14.15. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
Figure 14.16. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
Figure 14.17. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
Figure 14.18. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Commercial Operations (USD Billion)
Figure 14.19. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Figure 14.20. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
Figure 14.21. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 14.22. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 14.23. Microbial Contract Biomanufacturing Market in Europe, 2020-2030 (USD Billion)
Figure 14.24. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Proteins (USD Billion)
Figure 14.25. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Enzymes (USD Billion)
Figure 14.26. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Growth Hormones (USD Billion)
Figure 14.27. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Antibody based drugs (USD Billion)
Figure 14.28. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Biologics (USD Billion)
Figure 14.29. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
Figure 14.30. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
Figure 14.31. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
Figure 14.32. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Commercial Operations (USD Billion)
Figure 14.33. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Figure 14.34. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
Figure 14.35. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 14.36. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 14.37. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030 (USD Billion)
Figure 14.38. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Proteins (USD Billion)
Figure 14.39. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Enzymes (USD Billion)
Figure 14.40. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Growth Hormones (USD Billion)
Figure 14.41. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Antibody based drugs (USD Billion)
Figure 14.42. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Biologics (USD Billion)
Figure 14.43. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
Figure 14.44. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
Figure 14.45. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
Figure 14.46. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations (USD Billion)
Figure 14.47. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Figure 14.48. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies (USD Billion)
Figure 14.49. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 14.50. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 14.51. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030 (USD Billion)
Figure 14.52. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins (USD Billion)
Figure 14.53. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Enzymes (USD Billion)
Figure 14.54. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Growth Hormones (USD Billion)
Figure 14.55. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Antibody based drugs (USD Billion)
Figure 14.56. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Biologics (USD Billion)
Figure 14.57. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
Figure 14.58. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
Figure 14.59. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
Figure 14.60. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations (USD Billion)
Figure 14.61. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Figure 14.62. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Small Companies (USD Billion)
Figure 14.63. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 14.64. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 14.65. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030 (USD Billion)
Figure 14.66. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins (USD Billion)
Figure 14.67. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Vaccines (USD Billion)
Figure 14.68. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Biologics (USD Billion)
Figure 14.69. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Bacterial Cell-based Expression System (USD Billion)
Figure 14.70. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
Figure 14.71. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
Figure 14.72. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations (USD Billion)
Figure 14.73. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Figure 14.74. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Small Companies (USD Billion)
Figure 14.75. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 14.76. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 14.77. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030 (USD Billion)
Figure 14.78. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Proteins (USD Billion)
Figure 14.79. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Enzymes (USD Billion)
Figure 14.80. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Growth Hormones (USD Billion)
Figure 14.81. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Antibody based drugs (USD Billion)
Figure 14.82. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Biologics (USD Billion)
Figure 14.83. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
Figure 14.84. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
Figure 14.85. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
Figure 14.86. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Commercial Operations (USD Billion)
Figure 14.87. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Figure 14.88. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Small Companies (USD Billion)
Figure 14.89. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 14.90. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 15.1. Microbial Contract Biomanufacturing Market, 2017-2030: COVID-19 Impact
Figure 16.1. Microbial Contract Biomanufacturing Market: SWOT Analysis
Figure 16.2. Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables

Table 3.1. Mammalian versus Microbial Expression Systems
Table 4.1. List of Microbial Contract Biomanufacturers
Table 4.2. Microbial Contract Biomanufacturing: Information on Scale of Operation
Table 4.3. Microbial Contract Biomanufacturing: Information on Type of Biologic Manufactured
Table 4.4. Microbial Contract Biomanufacturing: Information on Type of Expression System Used
Table 4.5. Microbial Contract Biomanufacturing: Information on Type of Fermenter Used
Table 4.6. Microbial Contract Biomanufacturing: Information on Type of Service(s) Offered
Table 4.7. Microbial Contract Biomanufacturing: Information on Regulatory Accreditations / Certifications Obtained
Table 6.1. AGC Biologics: Company Overview
Table 6.2. AGC Biologics: Overview of Manufacturing Capabilities
Table 6.3. AGC Biologics: Recent Developments and Future Outlook
Table 6.4. Aldevron: Company Overview
Table 6.5. Aldevron: Overview of Manufacturing Capabilities
Table 6.6 Aldevron: Recent Developments and Future Outlook
Table 6.7. BioVectra: Company Overview
Table 6.8. BioVectra: Overview of Manufacturing Capabilities
Table 6.9. BioVectra: Recent Developments and Future Outlook
Table 6.10. Ology Bioservices: Company Overview
Table 6.11. Ology Bioservices: Overview of Manufacturing Capabilities
Table 6.12. Ology Bioservices: Recent Developments and Future Outlook
Table 6.13. Eurogentec: Company Overview
Table 6.14. Eurogentec: Overview of Manufacturing Capabilities
Table 6.15. Northway Biotechpharma: Company Overview
Table 6.16. Northway Biotechpharma: Overview of Manufacturing Capabilities
Table 6.17. Northway Biotechpharma: Recent Developments and Future Outlook
Table 6.18. Porton Biopharma: Company Overview
Table 6.19. Porton Biopharma: Overview of Manufacturing Capabilities
Table 6.20. EirGenix: Company Overview
Table 6.21. EirGenix: Overview of Manufacturing Capabilities
Table 6.22. Etinpro: Company Overview
Table 6.23. Etinpro: Overview of Manufacturing Capabilities
Table 6.24. Stelis Biopharma: Company Overview
Table 6.25. Stelis Biopharma: Overview of Manufacturing Capabilities
Table 6.26. Stelis Biopharma: Recent Developments and Future Outlook
Table 7.1. Microbial Contract Biomanufacturers: List of Partnerships, 2016-2020
Table 7.2. Microbial Contract Biomanufacturers: Acquisitions, 2016-2020
Table 7.3. Microbial Contract Biomanufacturers: Acquisitions by Key Value Drivers, 2016- 2020
Table 8.1. Microbial Contract Biomanufacturers: List of Expansions
Table 9.1. List of Technology Platforms for Microbial Manufacturing
Table 12.1. Big Pharmaceutical Players: List of Initiatives
Table 13.1. List of Microbial Contract Biomanufacturers
Table 13.2. Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 17.1. Microbial Contract Biomanufacturing Market: Key Takeaways
Table 19.1. Microbial Contract Biomanufacturers: Distribution by Year of Establishment
Table 19.2. Microbial Contract Biomanufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 19.3. Microbial Contract Biomanufacturers: Distribution by Company Size
Table 19.4. Microbial Contract Biomanufacturers: Distribution by Distribution by Location of Headquarters (Country-wise)
Table 19.5. Microbial Contract Biomanufacturers: Distribution by Location of Manufacturing Facilities (Country-Wise)
Table 19.6. Microbial Contract Biomanufacturers: Distribution by Scale of Operation
Table 19.7. Microbial Contract Biomanufacturers: Distribution by Type of Biologics Manufactured
Table 19.8. Microbial Contract Biomanufacturers: Distribution by Type of Expression System Used
Table 19.9. Microbial Contract Biomanufacturers: Distribution by Type of Fermenter Used
Table 19.10. Microbial Contract Biomanufacturers: Distribution by Type of Service(s) Offered
Table 19.11. Microbial Contract Biomanufacturers: Distribution by Regulatory Accreditations / Certifications Obtained
Table 19.12. Recent Partnerships: Cumulative Distribution by Year of Partnership
Table 19.13. Recent Partnerships: Distribution by Partnership Model
Table 19.14. Recent Partnerships: Year-wise Trend by Type of Partnership
Table 19.15. Recent Partnerships: Distribution by Scale of Operation
Table 19.16. Recent Partnerships: Distribution by Type of Biologic
Table 19.17. Recent Partnerships: Distribution by Focus Area
Table 19.18. Recent Partnerships: Distribution by Target Therapeutic Area
Table 19.19. Recent Partnerships: Country-Wise Distribution
Table 19.20. Recent Partnerships: Intercontinental and Intracontinental Deals
Table 19.21. Recent Partnerships: Most Active Players
Table 19.22. Acquisitions: Distribution by Year of Acquisition
Table 19.23. Acquisitions: Distribution by Type of Acquisition
Table 19.24. Acquisitions: Country-wise Distribution
Table 19.25. Acquisitions: Intercontinental and Intracontinental Acquisitions
Table 19.26. Acquisitions: Key Value Drivers
Table 19.27. Recent Expansions: Cumulative Distribution by Year of Expansion, 2016-2020
Table 19.28. Recent Expansions: Distribution by Type of Expansion
Table 19.29. Recent Expansions: Distribution by Scale of Operation
Table 19.30. Recent Expansions: Distribution by Type of Biologic
Table 19.31. Recent Expansion: Distribution by Geography
Table 19.32. Big Pharma Players: Distribution by Number of Microbial Biopharmaceutical Manufacturing Focused Initiatives
Table 19.33. Big Pharma Players: Cumulative Distribution by Year of Initiative
Table 19.34. Big Pharma Players: Distribution by Purpose of Initiative
Table 19.35. Big Pharma Players: Distribution by Type of Initiative
Table 19.36. Big Pharma Players: Distribution by Development Scale
Table 19.37. Big Pharma Players: Distribution by Type of Drug Molecule
Table 19.38. Big Pharma Players: Distribution by Type of Biologic Manufactured
Table 19.39. Big Pharma Players: Distribution by Type of Microbial Expression System Used
Table 19.40. Big Pharma Players: Distribution by Year of Initiative and Company
Table 19.41. Big Pharma Players: Distribution by Purpose of Initiative and Company
Table 19.42. Big Pharma Players: Distribution by Location of Initiative
Table 19.43. Big Pharma Players: Distribution by Location of Initiative and Company
Table 19.44. Microbial Contract Biomanufacturing: Distribution by Type of Product
Table 19.45. Microbial Contract Biomanufacturing: Distribution by Type of Expression System Used
Table 19.46. Overall Microbial Contract Biomanufacturing Market, 2020-2030 (USD Billion)
Table 19.47. Microbial Contract Biomanufacturing Market for APIs, 2020-2030 (USD Billion)
Table 19.48. Microbial Contract Biomanufacturing Market for FDFs, 2020-2030 (USD Billion)
Table 19.49. Microbial Contract Biomanufacturing Market: Distribution by Type of Biologic, 2020, 2025 and 2030
Table 19.50. Microbial Contract Biomanufacturing Market: Distribution by Type of Microbial Expression System Used, 2020, 2025 and 2030
Table 19.51. Microbial Contract Biomanufacturing Market: Distribution by Scale of Operation, 2020, 2025 and 2030
Table 19.52. Microbial Contract Biomanufacturing Market: Distribution by Type of End User, 2020, 2025 and 2030
Table 19.53. Microbial Contract Biomanufacturing Market: Distribution by Key Geographical Regions, 2020, 2025 and 2030
Table 19.54. Microbial Contract Biomanufacturing Market in North America, 2020-2030 (USD Billion)
Table 19.55. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Proteins (USD Billion)
Table 19.56. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Enzymes (USD Billion)
Table 19.57. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Growth Hormones (USD Billion)
Table 19.58. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Antibody based drugs (USD Billion)
Table 19.59. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Biologics (USD Billion)
Table 19.60. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
Table 19.61. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
Table 19.62. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
Table 19.63. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Commercial Operations (USD Billion)
Table 19.64. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Table 19.65. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
Table 19.66. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 19.67. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 19.68. Microbial Contract Biomanufacturing Market in Europe, 2020-2030 (USD Billion)
Table 19.69. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Proteins (USD Billion)
Table 19.70. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Enzymes (USD Billion)
Table 19.71. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Growth Hormones (USD Billion)
Table 19.72. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Antibody based drugs (USD Billion)
Table 19.73. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Biologics (USD Billion)
Table 19.74. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
Table 19.75. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
Table 19.76. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
Table 19.77. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Commercial Operations (USD Billion)
Table 19.78. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Table 19.79. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
Table 19.80. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 19.81. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 19.82. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030 (USD Billion)
Table 19.83. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Proteins (USD Billion)
Table 19.84. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Enzymes (USD Billion)
Table 19.85. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Growth Hormones (USD Billion)
Table 19.86. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Antibody based drugs (USD Billion)
Table 19.87. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Biologics (USD Billion)
Table 19.88. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
Table 19.89. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
Table 19.90. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
Table 19.91. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations (USD Billion)
Table 19.92. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Table 19.93. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies (USD Billion)
Table 19.94. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 19.95. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 19.96. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030 (USD Billion)
Table 19.97. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins (USD Billion)
Table 19.98. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Enzymes (USD Billion)
Table 19.99. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Growth Hormones (USD Billion)
Table 19.100. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Antibody based drugs (USD Billion)
Table 19.101. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Biologics (USD Billion)
Table 19.102. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
Table 19.103. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
Table 19.104. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
Table 19.105. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations (USD Billion)
Table 19.106. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Table 19.107. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Small Companies (USD Billion)
Table 19.108. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 19.109. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 19.110. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030 (USD Billion)
Table 19.111. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins (USD Billion)
Table 19.112. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Vaccines (USD Billion)
Table 19.113. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Biologics (USD Billion)
Table 19.114. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Bacterial Cell-based Expression System (USD Billion)
Table 19.115. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
Table 19.116. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
Table 19.117. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations (USD Billion)
Table 19.118. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Table 19.119. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Small Companies (USD Billion)
Table 19.120. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 19.121. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 19.122. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030 (USD Billion)
Table 19.123. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Proteins (USD Billion)
Table 19.124. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Enzymes (USD Billion)
Table 19.125. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Growth Hormones (USD Billion)
Table 19.126. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Antibody based drugs (USD Billion)
Table 19.127. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Biologics (USD Billion)
Table 19.128. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
Table 19.129. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
Table 19.130. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
Table 19.131. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Commercial Operations (USD Billion)
Table 19.132. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Table 19.133. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Small Companies (USD Billion)
Table 19.134. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 19.135. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 19.136. Microbial Contract Biomanufacturing Market, 2017-2030: COVID-19 Impact Informed Scenario (USD Billion)

List Of Company

The following companies and organizations have been mentioned in the report.

  1. 3P Biopharmaceuticals
  2. 3SBio
  3. 53Biologics
  4. AbbVie
  5. AbbVie Contract Manufacturing
  6. Adare Pharmaceuticals
  7. ADL Bionatur Solutions 
  8. ADL BioPharma
  9. ADM Biopolis
  10. Advaxis
  11. Affibody
  12. Affinity Life Sciences
  13. AGC Biologics
  14. Ajinomoto Bio-Pharma Services
  15. Akers Biosciences
  16. Akshaya Bio
  17. Aldevron
  18. Allergan
  19. Alliance Protein Laboratories
  20. Altor BioScience
  21. Amgen
  22. AMRI
  23. Arranta Bio
  24. AstraZeneca
  25. Aumgene Biosciences
  26. AURA Biotechnologies
  27. Axcellerate Pharma
  28. BacThera
  29. Batavia Biosciences
  30. Bexion Pharmaceuticals
  31. BIA Separations
  32. BINEX
  33. Bio Elpida
  34. BioCell
  35. Biological E. 
  36. BioMARC
  37. Biomay
  38. Biomeva (Acquired by AGC)
  39. Bionaturis
  40. BioProduction by Sekisui
  41. Biose industrie
  42. Biosynergy (Europe)
  43. Bio-Synthesis
  44. Bio-Technology General
  45. BioVectra
  46. Biovian
  47. BJP Laboratories
  48. Boehringer Ingelheim
  49. Boehringer Ingelheim BioXcellence
  50. Boston Institute of Biotechnology
  51. Bristol-Myers Squibb
  52. Capsugel 
  53. Captozyme (Acquired by Arranta Bio) 
  54. Capua BioServices
  55. Cara Therapeutics
  56. Cerbios-Pharma
  57. Charles River Laboratories
  58. ChemPartner
  59. CinnaGen
  60. Citryll 
  61. Clovis Oncology
  62. Cobra Biologics
  63. Corden BioChem
  64. Creative Biolabs
  65. Cytovance Biologics
  66. Dyadic International
  67. EirGenix
  68. EKF Life Sciences
  69. Eli Lilly
  70. Elion Labs 
  71. Emergent BioSolutions
  72. Enteris BioPharma
  73. Etinpro
  74. EuBiologics
  75. Eucodis Bioscience
  76. Eurogentec
  77. Evonik Health Care
  78. Fermentalg
  79. Ferring Pharmaceuticals
  80. Finox 
  81. Fresenius Medical Care 
  82. FUJIFILM Diosynth Biotechnologies
  83. GE Healthcare
  84. GenIbet Biopharmaceuticals
  85. Genome & Company
  86. GreenPak Biotech 
  87. Griffith University
  88. GSK Contract Manufacturing  
  89. GT Biopharma
  90. GTP Technology
  91. Hansa Biopharma
  92. Hong Kong Institute of Biotechnology
  93. Inovio Pharmaceuticals
  94. Inpac Probiotics 
  95. Jeneil Biotech
  96. Johnson & Johnson
  97. Kanda BioTech
  98. KBI Biopharma
  99. Keryx Biopharmaceuticals
  100. KeyBioscience
  101. LakePharma
  102. List Biological Laboratories
  103. LNC Therapeutics
  104. Lonza
  105. Luina Bio
  106. Maine Biotechnology Services
  107. Menarini Biotech
  108. Merck
  109. Merck Millipore
  110. Meridian Life Science
  111. Meteoric Biopharmaceuticals
  112. MicroBiopharm Japan 
  113. Mologic
  114. Mycenax Biotech
  115. Nature Technology
  116. Nebraska Cultures
  117. NIZO
  118. Northway Biotechpharma 
  119. Novartis
  120. Novo Nordisk
  121. NUMAFERM 
  122. Ology Bioservices
  123. Olon
  124. Omeros
  125. Oncobiologics
  126. Orbis Biosciences
  127. Panacea Biotec
  128. Paragon Bioservices (unit of Catalent Biologics)
  129. Paras Biopharmaceuticals Finland
  130. PEPDesign 
  131. Pfizer
  132. Pfizer CentreOne
  133. PhaseBio
  134. Pierre Fabre
  135. Polpharma Biologics
  136. Polymun Scientific
  137. Portola Pharmaceuticals
  138. Porton Biopharma
  139. Premas Biotech
  140. PrEP Biopharm 
  141. ProbioFerm
  142. Probiotical
  143. Proteon Therapeutics
  144. Protexin
  145. Proventus Bioscience
  146. PX’Therapeutics
  147. Quantum Hi-Tech China Biological
  148. Quay Pharma
  149. Reliance Life Sciences
  150. Richter-Helm BioLogics
  151. Roche
  152. Sandoz
  153. Sanofi
  154. Scientific Protein Laboratories (SPL)
  155. Scil Proteins Pharma
  156. Siam Bioscience
  157. SiliCycle
  158. Stelis BioSource™ (manufacturing arm of Stelis Biopharma)
  159. SynCo Bio 
  160. Syngene
  161. Takara Bio
  162. Taron Solutions
  163. The Native Antigen Company
  164. Therapure Biopharma
  165. TUBE Biopharmaceuticals 
  166. UAS Labs
  167. Unique Biotech
  168. Vectron Biosolutions
  169. Vestaron
  170. VGXI
  171. Vibalogics
  172. Vigene Biosciences
  173. VTU Technology
  174. VxP Biologics
  175. WACKER Biotech
  176. Waisman Biomanufacturing
  177. Winclove Probiotics
  178. WuXi Biologics
  179. XL-protein
  180. Zhejiang Hisun Pharmaceutical
  181. Zhittya Genesis Medicine

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © Roots Analysis. All Rights Reserved.